Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company ...
A multicenter prospective study to evaluate the efficacy of resection for initially unresectable hepatocellular carcinoma after atezolizumab combined with bevacizumab (the RACB study): Short-term ...
Chinese researchers have revealed a mechanism that triggers metastasis of hepatocellular carcinoma (HCC)—the most common type of primary liver cancer—through the production of acetate by ...
This case presents a progression from benign focal nodular hyperplasia (FNH) to hepatocellular carcinoma (HCC) in a ...
Hepatocellular carcinoma (HCC) is one of the deadliest malignant tumors in the world, and its incidence and mortality have increased year by year. HCC research has increasingly focused on ...
Chinese researchers have revealed a mechanism that triggers metastasis of hepatocellular carcinoma (HCC)—the most common type of primary liver cancer—through the production of acetate by ...
Real-World Utilization and Performance of Circulating Tumor DNA Monitoring to Predict Recurrence in Solid Tumors Hepatocellular carcinoma (HCC) has an increasing incidence and global mortality burden.
PET-CT imaging with [18 F]fluorodeoxyglucose (FDG) and [18 F]fluorocholine (FCH) altered treatment plans in only a tiny minority of patients undergoing initial staging for hepatocellular carcinoma ...
Liver cancer incidence is rising in the Netherlands, driven by MASLD-related disease. Find out what the nationwide study means for clinical practice.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results